Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration

Retina

Volumn 36, Issue 8, 2016, Pages 1418-1431

  Kim, Leah N ^a   Mehta, Hemal ^a,b   Barthelmes, Daniel ^a,c   Nguyen, Vuong ^a   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Age related macular degeneration; Neovascular; Observational; Ranibizumab; Real world outcomes

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; AGE RELATED MACULAR DEGENERATION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; META ANALYSIS; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84978052527     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001142     Document Type: Review

References (58)

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014; 2: E106-e116.
2. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96: 614-618.
3. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Syst Rev 2014; 8: 1-155.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for noevascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
6. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
7. Higgins J, Thompson SG. Quantifying heterogeneity in metaanalysis. Stat Med 2002; 21: 1539-1558.
8. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software 2010; 36: 1-48.
9. Furukawa TA, Barbui C, Cipriani A. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006; 59: 7-10.
10. Thiessen Philbrook H, Barrowman N, Garg AX. Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: A case study of changes in renal function after living kidney donation. J Clin Epidemiol 2007; 60: 228-240.
11. Team RC. R: A Language and Environmental for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
12. Buuren S, Groothuis-Oudshoorn K. Mice: Multivariate imputation by chained equations in R. J Stat Software 2011; 45: 1-67.
13. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220-226.
14. Heimes B, Lommatzsch A, Zeimer M, et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 2011; 249: 639-644.
15. Pushpoth S, Sykakis E, Merchant K, et al. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96: 1469-1473.
16. Katz G, Giavedoni L, Muni RH, et al. Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to agerelated macular degeneration. Retina 2012; 32: 293-298.
17. Abedi F, Wickremasinghe S, Islam AFM, et al. Anti-VEGF Treatment in neovascular age-related macular degeneration: A treat-and-extend protocol over 2 years. Retina 2014; 34: 1531-1538.
18. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration: From randomized trials to clinical practice. Eye (Lond) 2009; 23: 1633-1640.
19. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: Results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011; 2011: 405724.
20. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117: 2134-2140.
21. Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: Long-term safety of ranibizumab 0.5 mg in neovascular agerelated macular degeneration. Ophthalmology 2013; 120: 130-139.
22. Souied EH, Oubraham H, Mimoun G, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice-The TWIN study. Retina 2015: 1-7.
23. van Asten F, Evers-Birkenkamp KU, van Lith-Verhoeven JJ, et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2015; 93: 126-133.
24. Frennesson CI, Nilsson SE. A three-year follow-up of ranibizumab treatment of exudative AMD: Impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmol 2014; 92: 216-220.
25. Mantel I, Niderprim SA, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular agerelated macular degeneration using an individually planned regimen. Br J Ophthalmol 2014; 98: 1192-1196.
26. Menghini M, Kloeckener-Gruissem B, Fleischhauer J, et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular agerelated macular degeneration. PLoS One 2014; 7: E42014.
27. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: Data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 2014; 252: 647-655.
28. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice. Retina 2013; 33: 474-481.
29. Falk MK, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013; 155: 89-95 e83.
30. Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013; 91: 540-546.
31. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the luminous programme. Br J Ophthalmol 2013; 97: 1161-1167.
32. Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study. Clin Ophthalmol 2013; 7: 1849-1858.
33. Biarnés M, Monés J, Villalbi JR, Arias L. As-needed treatment with ranibizumab 0.5 mg in patients with neovascular agerelated macular degeneration. Eur J Ophthalmol 2011; 21: 282-289.
34. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed. Retina 2011; 31: 26-30.
35. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010; 94: 292-296.
36. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009; 148: 409-413.
37. Rothenbuehler SP, Waeber D, Brinkmann CK, et al. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009; 147: 831-837.
38. Writing Committee for the U.K. Age-Related Macular Degeneration E.M.R. Users Group. The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity. Ophthalmology 2014; 121: 1092-1101.
39. Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes. Ophthalmology 2014; 121: 1966-1975.
40. Muniraju R, Ramu J, Sivaprasad S. Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmologica 2013; 230: 27-33.
41. Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2010; 4: 1271-1275.
42. Rayess N, Houston SK III, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015; 159: 3-8.
43. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299.
44. Bellerive C, Cinq-Mars B, Lalonde G, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: A treatment approach based on individual patient needs. Can J Ophthalmol 2012; 47: 165-169.
45. Bandukwala T, Muni RH, Schwartz C, et al. Effectiveness of intravitreal ranibizumab for the treatment of neovascular agerelated macular degeneration in a Canadian retina practice: A retrospective review. Can J Ophthalmol 2010; 45: 590-595.
46. Engelbert M, Zweifel SA, Freund B. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010; 30: 1368-1375.
47. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116: 1740-1747.
48. Barthelmes D, Walton R, Campain AE, et al. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: Observational study data. Br J Ophthalmol 2015; 99: 359-364.
49. Gillies MC, Campain A, Walton R, et al. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology 2015; 122: 589-594 e581.
50. Arnold JJ, Campain A, Barthelmes D, et al. Two year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. in Sydney TUo ed., 2015; 122: 1212-1219.
51. Barthelmes D, Walton RJ, Arnold JJ, et al. Intravitreal therapy in bilateral neovascular age-related macular degeneration. Ophthalmology 2014; 121: 2073-2074.
52. Gillies MC, Walton RJ, Arnold JJ, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology 2014; 121: 676-681.
53. Gillies MC, Walton R, Simpson JM, et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci 2013; 54: 5754-5760.
54. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of agerelated macular degeneration. Retina 2013; 33: 1351-1358.
55. López-López JA, Marin-Martinez F, Sánchez-Meca J, et al. Estimation of the predictive power of the model in mixedeffects meta-regression: A simulation study. Br J Math Stat Psychol 2014; 67: 30-48.
56. Lee AY, Lee CS, Butt T, et al. UK AMD EMR Users Group Report V: Benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol 2014; 99: 1045-1050.
57. Rodrigues IA, Sprinkhuizen SM, Barthelmes D, et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. Am J Ophthalmol 2016; 168: 1-12.
58. Gillies MC, Walton R, Liong J, et al. Efficient capture of highquality data on outcomes of treatment for macular diseases. Retina 2013: 1-8.